Akorn, Natco sign deal to develop, supply two generic drugs with $800 million market

By E. Janene Geiss

Philadelphia, Dec. 19 - Akorn, Inc. announced Monday that it has signed a letter of intent with Natco Pharma Ltd. to develop and supply two Abbreviated New Drug Application oral tablets for cancer patients suffering from nausea and vomiting.

The companies expect to sign a definitive agreement within 90 days, according to a company news release.

The two generic drug products will focus on the anti-emetic market, officials said, and have a current market size of about $800 million.

Natco will be responsible for the development and manufacturing of both drug products, while Akorn will be responsible for marketing and distribution in the hospital, clinic and home health care markets in the United States and Canada.

"We are excited to pursue the development and commercialization of these two drugs with our newest partner, Natco Pharma. These drug products will complement our oncology line of injectable products already in development," said Arthur S. Przybyl, Akorn's president and chief executive officer, in the news release.

Akorn, based in Buffalo Grove, Ill., manufactures and markets sterile specialty pharmaceuticals.

Natco is an integrated pharmaceutical company based in Hyderabad, Andhra Pradesh, India.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.